drug-discovery

Nvidia released Cosmos 3 Edge, a world model designed for robots and vision AI agents to perceive and navigate physical environments in real time. The company announced partnerships with Japanese industrial giants including Fujitsu, Hitachi, and Kawasaki Heavy Industries as part of its physical AI expansion.

Anthropic is starting an internal drug discovery program focused on neglected diseases while launching Claude Science, a product designed for pharmaceutical companies. Life sciences head Eric Kauderer-Abrams said the program aims to provide feedback for developing better AI tools for drugmakers.

OpenAI has released GPT-Rosalind, a large language model trained specifically on 50 common biology workflows and major biological databases. Unlike broader science-focused models from competitors, GPT-Rosalind targets specialized biology tasks including pathway analysis, drug target prioritization, and cross-disciplinary research navigation.